This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
(1) studies had to contain outcomes related to RR and AMI, and to report clinical incidents according to ICD-9 diagnosis codes for hospitalisation statistics;
(2) studies had to report age-adjusted RRs; (3) studies had to have either a case-control design reporting RRs adjusted for a number of co-factors and effect modifiers or to be a population-based study potentially applicable to the US; (4) studies had to adjust for pre-existing confounders to reduce the possible effect of "quitting sick effect" on the RR estimates.
Two studies used for the estimation of the fall in the risk of stroke after smoking cessation were prospective cohort studies. Three studies used for AMI were reported to be retrospective case-control studies.
Sources searched to identify primary studies
Not reported.
Criteria used to ensure the validity of primary studies
Methods used to judge relevance and validity, and for extracting data
Number of primary studies included
A total of 16 studies were directly used as the references for the outcomes assessed in the review.
Methods of combining primary studies
A meta-analysis could not be applied since the studies did not have similar time horizons, instead the data were combined and a function for the fall in RR as a function of time was estimated using a functional form of exponential decay in the ln RR. Regression estimates were used to calculate the average RRs for all current smokers and exsmokers.
Investigation of differences between primary studies
Results of the review
The following outcome results for males and females were related to AMI:
proportion of smokers, 0.301 (male) and 0.250 (female);
proportion of ex-smokers, 0.288 (m) and 0.205 (f); observed incidence in the population, 0.00502 (m) and 0.00159 (f); annual survival probability, 0.99163 (m) and 0.99497 (f); annual survival probability after event for first year, 0.812 (m) and 0.765 (f); annual survival probability after event for second and following years, 0.944 (m) and 0.933 (f) .
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The following outcome results were related to stroke (for both male and female):
proportion of smokers, 0.275;
proportion of ex-smokers, 0.245; observed incidence in the population, 0.00219; annual survival probability, 0.99334; annual survival probability after event for first year, 0.663; annual survival probability after event for second and following years, 0.961.
Methods used to derive estimates of effectiveness
Assumptions about effectiveness were also made by the authors.
Estimates of effectiveness and key assumptions
Smokers and ex-smokers without the experience of an event were "assumed to have the annual survival probability of the average current smoker aged 35 to 64". A person with an experience of hospitalisation at year t was "assumed to have the averageannual survival probability for the first year after hospitalisation". It was assumed that "the RR of events for smokers versus non-smokers was the same for first and subsequent events".
Measure of benefits used in the economic analysis
The measure of benefits was cases of AMI and stroke avoided annually for two patterns of cessation: one-time 1% reduction in smoking prevalence, and annual (up to 7 years) 1% reduction in smoking prevalence.
Direct costs
Costs were discounted. Resource utilisation was not fully reported separately from the costs. The cost items were not reported separately. The cost analysis covered the direct medical cost of initial treatment of AMI, the expected costs of major surgical procedures related to AMI, the annual cost of follow-up and rehabilitation related to AMI, short-term costs of treatment of stroke, rehabilitation costs of stroke, and costs of care in nursing facilities. The direct medical cost covered the operating costs. The resource use and cost data were extracted from the literature. Medicare cost-tocharge ratio was used to translate the charges to true costs. The perspective adopted in the cost analysis was not explicitly specified. The price date was 1995. The cost of thrombolytic therapy was not included in the analysis.
Indirect Costs
Not considered.
Currency

US dollars ($).
Sensitivity analysis
A one-way simple sensitivity analysis was performed on discount rate. Multiple Monte Carlo simulations for acute myocardial infarction and stroke were carried out.
Estimated benefits used in the economic analysis
The number of cases (standard deviation) of AMI and stroke avoided annually for two patterns of cessation
